share_log

Roche Huntington-Disease Trial Halt Seen as Setback to Sentiment -- Market Talk

Roche Huntington-Disease Trial Halt Seen as Setback to Sentiment -- Market Talk

罗氏亨廷顿-疾病试验暂停被视为人气受挫-市场谈话
Dow Jones Newswires ·  2021/03/23 16:49

DJ Roche Huntington-Disease Trial Halt Seen as Setback to Sentiment -- Market Talk

DJ罗氏亨廷顿-疾病试验暂停被视为情绪受挫-市场谈话

0849 GMT - The halt to Roche's phase-3 trial of Huntington-disease drug tominersen is presumably because the drug has insufficient efficacy, Jefferies says. Given the fact that tominersen was widely wiewed to be a significant blockbuster option in the Swiss major's pipeline, this news is a setback to sentiment, according to Jefferies. The drug had potential as a blockbuster asset, considering that no therapies are currently approved to slow the progression of the disease, Jefferies says.The investment bank reiterates its hold recommendation on Roche's stock. Roche trades down 1.8% at CHF309.35. (cecilia.butini@wsj.com)

0849GMT-杰弗瑞说,罗氏暂停亨廷顿病药物Tominesen的3期试验大概是因为该药物疗效不足。杰富瑞表示,鉴于托马纳森被广泛认为是这位瑞士少校未来的重要重磅炸弹选择,这一消息对市场人气来说是一个挫折。Jefferies说,考虑到目前还没有批准任何延缓疾病进展的疗法,这种药物有潜力成为一项重磅资产。这家投资银行重申了对罗氏股票的持有建议。罗氏股价下跌1.8%,至309.35瑞士法郎。(cecilia.butini@wsj.com)

(END) Dow Jones Newswires

(完)道琼通讯社

March 23, 2021 04:49 ET (08:49 GMT)

美国东部时间2021年3月23日04:49(格林尼治标准时间08:49)

Copyright (c) 2021 Dow Jones & Company, Inc.

版权所有(C)2021年道琼斯公司

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发